Search results
Results From The WOW.Com Content Network
AstraZeneca plc (/ ˌ æ s t r ə ˈ z ɛ n ə k ə /) (AZ) is a British-Swedish [2] [3] [4] multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, United Kingdom. [5]
A study published in April 2021 by researchers from the COVID-19 Genomics United Kingdom Consortium, the AMPHEUS Project, and the Oxford COVID-19 Vaccine Trial Group indicated the Oxford–AstraZeneca vaccine showed somewhat reduced efficacy against infection with the Alpha variant (lineage B.1.1.7), with 70.4% efficacy in absolute terms ...
APS – TEVA UK Ltd; Assertio – Assertio Therapeutics, Inc; AstraZeneca – AstraZeneca UK Limited; Aventis Pharma – Sanofi-Aventis Ltd; Bausch & Lomb – Bausch & Lomb UK Ltd; Baxter – Baxter International; Baxter BioScience – Baxter International; Bayer – Bayer plc (Pharmaceutical Division) Becton Dickinson – Becton Dickinson UK Ltd
By Yadarisa Shabong (Reuters) -AstraZeneca said on Tuesday it will buy clinical-stage biopharmaceutical company Fusion Pharmaceuticals Inc for about $2 billion in cash as the Anglo-Swedish ...
Zeneca (officially Zeneca Group PLC) was a British multinational pharmaceutical company headquartered in London, United Kingdom.It was formed in June 1993 by the demerger of the pharmaceuticals and agrochemicals businesses of Imperial Chemical Industries into a separate company listed on the London Stock Exchange.
(Reuters) -Britain's competition regulator is reviewing AstraZeneca's planned $39 billion takeover of U.S.-based Alexion on whether it could reduce competition in Britain or other markets. The UK ...
London-listed AstraZeneca began moving into respiratory syncytial virus vaccines and obesity drugs through several deals last year after a slowdown in growth as COVID-19 medicine sales declined.
“We believe that these assets have the potential to positively impact Oncology R&D and will support the development of new and improved therapies for cancer patients.” AstraZeneca has agreed to pay Achilles Therapeutics $12M for the assets in total. BofA Securities provided strategic financial advice to Achilles for the transaction.